The FDA has requested the withdrawal of obeticholic acid (Ocaliva), used to treat primary biliary cholangitis (PBC). Manufacturer Intercept Pharmaceuticals announced the drug will remain available during a 60-day transition period ending Nov. 14, 2025, after which it will no longer be commercially sold in the U.S.
Keep Reading
Add A Comment